Introduction : People with chronic kidney disease (CKD) of stages 3-5 (creatinine clearance < 60 ml/min) represent 25-30% of patients with type 2 diabetes (T2DM), but the problem is underrecognized or neglected in clinical practice. However, most oral antidiabetic agents have limitations in case of renal impairment, either because they require a dose adjustment or because they are contraindicated for safety reasons. Expert Opinion : Because of potential important PK interferences and for safety reasons, the pharmacological management of T2DM should be adjusted according to kidney function. In general, the daily dose should be reduced according to glomerular filtration rate (GFR) or even the drug is contraindicated in presence of more severe CKD. This is the case for metformin (risk of lactic acidosis) and for many sulfonylureas (risk of hypoglycemia). At present, however, the exact GFR cutoff for metformin use is controversial. New antidiabetic agents are better tolerated in case of CKD, although clinical experience remains quite limited for most of them. The dose of DPP-4 inhibitors should be reduced (except for linaglitpin) whereas both the efficacy and safety of SGLT2 inhibitors are questionable in presence of CKD.
Introduction
The prevalence of type 2 diabetes mellitus (T2DM) is rapidly increasing worldwide.
Numerous patients with T2DM have some degree of renal impairment (RI), which may be assessed by a reduction in glomerular filtration rate (GFR) and classified in various stages according to severity (from stage 1 to stage 5) 1, 2 . The presence of RI may impact on the management of T2DM 3, 4 . The prevalence of chronic kidney disease (CKD) associated with diabetes in the United States increased from 1988 to 2008 in proportion to the prevalence of diabetes and among persons with diabetes, the prevalence of CKD was stable despite the implementation of specific therapies 5 . The causes of CKD in T2DM patients are numerous, most generally combining the effects of diabetic nephropathy resulting from chronic hyperglycemia (which may remain unknown for a long time because of the lack of symptoms), nephroangiosclerosis secondary to arterial hypertension (a common comorbidity in patients with T2DM), urinary infections (generally asymptomatic), coadministered potentially nephrotoxic agents (among which widely used non steroidal antiinflammatory drugs) or simply advance in age 3 .
In the US National Health and Nutrition Examination Survey (NHANES), 39.7 % of patients with T2DM had CKD of various degrees 6 . The proportion of patients treated by at least one oral antidiabetic agent (OAD) significantly progresses from 36.3% in patients with stage 1 CKD to 62.9% in patients with stages 4-5 CKD. These observations support the availability of efficacious and safe glucose-lowering agents to be prescribed in T2DM patients with CKD. In the Kidney Early Evaluation Program (KEEP) involving 77,077 participants, 26 .2% had CKD and 29.9% had diabetes. Among those with both diabetes and CKD, only 9.4% were aware of the existence of RI 7 . Interestingly, patients with a documented RI diagnosis have lower odds of progression to end-stage renal disease (ESRD). The presence of CKD may influence the adequate use of glucose-lowering agents in T2DM [8] [9] [10] . Not surprisingly, commonly prescribed OADs such as metformin and sitagliptin are frequently administered at inappropriate doses in patients with RI 11 . These observations reinforce the need for a better sensitization of both physicians and diabetic patients regarding the problem of CKD. The general objectives are that T2DM patients should be regularly checked as far as their renal function and that glucose-lowering agents are used in an efficacious and safe manner in presence of CKD [12] [13] [14] . Finally, besides specific hyperglycemia management, other risk factors (hypertension, dyslipidemias, …) should also be treated in order to improve cardiovascular and renal outcomes 2, 3, 12, 15 .
Evidence that intensive glucose-lowering treatment has an effect on loss of glomerular filtration rate (GFR) is sparse. The 2012 update of the KDOQI (Kidney Disease Outcomes Quality Initiative) clinical practice guidelines for diabetes and CKD recommends a target hemoglobin A1c (HbA1c) of ≈ 7.0% to prevent or delay progression of the microvascular complications of diabetes, including CKD (level of evidence 1A); recommends not treating to an HbA1c target of <7.0% in patients at risk of hypoglycemia (level of evidence 1B); and suggests that target HbA1c be extended above 7.0% in individuals with co-morbidities or limited life expectancy and risk of hypoglycemia (level of evidence 2C) Kidney plays a major role in the clearance of drugs, in general 17 , and of glucoselowering agents used for T2DM, in particular 13 . Therefore, the management of glycemia in patients with diabetes and CKD is quite challenging 10 and the questions of which hypoglycemic agents to use in T2DM subjects with CKD and how to use them are of major practical importance 18 . Besides the mode of action of glucose-lowering agents 19 , renal function should also be taken into account by the physician. Indeed, the presence of RI may deeply impact the pharmacokinetics (PK) and thereby should influence choices, dosing, and monitoring of hypoglycemic agents according to the reduction of GFR 9 . The situation is even more complex in the frail elderly population, where RI and polymedication are very common 20 .
The aim of this paper is to provide an updated analysis of the use of OADs and injectable agents in T2DM patients with CKD [8] [9] [10] . After a brief description of how to assess kidney function in patients with T2DM, we will describe the PK characteristics as well as the efficacy/safety profile of each glucose-lowering compound in patients with various degrees of RI ( Table 1, Table 2 ).
To identify relevant studies, an extensive literature search of MEDLINE was performed from 1970 to December 2012, with the names of the following pharmacological classes biguanides, sulfonylureas, meglitinides (glinides), alpha-glucosidase inhibitors, thiazolidinediones (TZDs), dipeptidyl peptidase-4 (DPP-4) inhibitors, sodium-glucose cotransporter-2 (SGLT2) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, human insulin or insulin analogs combined with any of the following terms : "chronic kidney disease", "renal insufficiency", "renal impairment" or "nephropathy". Each generic name -"metformin", glibenclamide (glyburide), glimepiride, glipizide, gliclazide, gliquidone, repaglinide, nateglinide, acarbose, miglitol, voglibose, pioglitazone, rosiglitazone, sitagliptin, vildagliptin, saxagliptin, linagliptin, alogliptin, dapagliflozin, canagliflozin, empagliflozin, exenatide, liraglutide, insulin, insulin lispro, insulin aspart, insulin glulisine, insulin glargine, insulin detemir -was also combined with the various terms corresponding to CKD. No language restrictions were imposed. Reference lists of original studies, narrative reviews and previous systematic reviews were also carefully examined.
Assessment of kidney function and stratification of CKD in diabetes
Renal function is classically assessed by the GFR, which can be estimated by the creatinine clearance (CL CR ) using the Cockroft-Gault formula 1 . However, such formula may be biased by body weight as a confounding factor leading to overestimation of true GFR in overweight/obese individuals, a common situation in patients with T2DM. Currently, the MDRD (« Modification of Diet in Renal Disease « ) formula is preferred as the method of choice for estimating GFR (eGFR), although it underestimates GFR in patients with GFR > 60 mL/min/1.73 m² body surface area and is not validated for all populations. The corresponding values to the various stages of RI are summarized in Table 3 . More appropriate new formulae have been recently proposed by nephrologists, although they are not used yet in clinical practice by diabetologists 21 . However, the coexistence of two formulae, such as Cockroft-Gault and MDRD, may lead to some discrepancies in dosing adjustment as recently illustrated with the use of sitagliptin in clinical practice 22 .
Biguanides (metformin)
Among biguanide compounds, only metformin remains on the market. The two other agents, phenformin and buformin, were withdrawn because of a too high risk of lactic acidosis, especially when the compound accumulates in case of RI 23 . Although this complication may also occur with metformin, it is a rare event when the contraindications are respected but, interestingly enough, also in patients who may be considered at higher risk (see below) 24 . Metformin is currently accepted as the first choice OAD in the management of T2DM 16 . Paradoxically, there are numerous contraindications to the use of metformin because of a theoretical risk of lactic acidosis 24 . However, such a risk has been probably overestimated in many circumstances. Therefore, contraindications to the use of metformin may deprive numerous T2DM patients from a drug that may provide more benefits than risks 25, 26 . This is especially the case of patients with mild to moderate CKD who deserve much attention because they represent an increasing proportion of the T2DM population, notably in the elderly 20 .
PK characteristics of metformin are well known since a long time ago 27 , even if new interesting mechanistic data have been published more recently 28 . Metformin is absorbed predominately from the small intestine and is excreted unchanged in urine. The elimination half-life (t 1/2 ) of metformin during multiple dosages in patients with good renal function is approximately 5 hours. The population mean renal clearance (CL R ) and apparent total clearance after oral administration (CL/F) of metformin were estimated to be (mean±SD) 510±130 mL/min and 1140±330 mL/min, respectively, in healthy subjects and diabetic patients with good renal function. Over a range of renal function, the population mean values of CL R and CL/F of metformin are 4.3±1.5 and 10.7±3.5 times as great, respectively, as the CL CR . As the CL R and CL/F decrease approximately in proportion to CL CR , the dosage of metformin should be reduced in patients with CKD in proportion to the reduced CL CR 28 .
However, rather few PK data are available in T2DM patients with various degrees of RI.
More recent data revealed that the renal excretion of metformin (as its oral absorption and hepatic uptake) is mediated largely by organic cation transporters (OCTs) 28 . CL R of metformin in healthy Caucasian men varied 3.8-fold and was significantly dependent not only on CL CR and age but also on OCT1 polymorphisms 29 . Finally, promoter variants of multidrug and toxin extrusion protein (MATE)1 and MATE2 were recently shown to be also important determinants of metformin disposition, by influencing its renal and secretory clearances, and glucose-lowering response in healthy volunteers and diabetic patients 30 .
PK of metformin after single dose in patients with RI
PK parameters of metformin were determined in volunteers with normal renal function and in patients with different degrees of RI. The t 1/2 for the elimination of metformin from plasma after intravenous injection was much longer (4.94±1.11 h) in patients with RI than in normal subjects (1.52±0.3 h). A significant correlation was observed between t 1/2 and CL CR .
After oral administration of metformin tablets, drug recovery in urines was only 37.6%, possibly as a consequence of binding to the intestinal wall. Metformin is rapidly eliminated through active secretion by the kidney, with a mean CL R of 440 ml/min (almost 3-4 times the value of CL CR ) 31 . Another study in healthy subjects and T2DM patients with various degrees of RI gave information about metformin clearance over a range of CL CR from 47 to 179 mL/min. Plasma CL R of metformin was found to be highly correlated with CL CR (r = 0.85, P<0.001). However, a weaker relationship between total oral clearance of the drug and CL CR suggested that the latter may not always be a reliable indicator of potential metformin accumulation. CL R values for metformin well in excess of CL CR confirmed tubular secretion of this highly ionized compound as a major mechanism of urinary excretion 32 .
In a detailed study evaluating the effects of RI and age on the PK of metformin, healthy adults (young, middle-age, elderly) and adults with various degrees of CKD (mild to severe) were given a single, 850 mg metformin HCl tablet 33 . In the control group (CL CR :
112±8 mL/min), average metformin CL R was 636±84 mL/min, whereas in mild CKD (CL CR : 61-90 mL/min) metformin CL R was reduced at 384±122 mL/min. The mean CL R of metformin was lower in subjects with moderate (CL CR : 31-60 mL/min) and severe (CL CR :
10-30 mL/min) CKD, measuring 108±57 and 130±90 mL/min, respectively. Maximum concentration (C max ) and the area under the concentration time curve (AUC) were increased in individuals with moderate to severe CKD compared with those with mild CKD or normal renal function. In the moderate and severe CKD groups, all clearance values were 74-78% lower than in the healthy young/middle-age group, and all other evaluable PK parameters (with the exception of t max ) differed significantly in this group. In the mild CKD group, however, clearance values of metformin, which were 23-33% lower than in the young/middleage group, were the only parameters that differed significantly. Based on a regression analysis of the combined data, both CL CR and age were predictors of metformin clearance 33 .
In healthy elderly subjects (mean age : 71 years; range : 65-81 years), total plasma clearance of metformin was decreased, the half-life was prolonged, and C max was increased, compared to healthy young subjects. From these data, it appears that the change in metformin PK with aging is primarily accounted for by a change in renal function. Metformin CL R averaged 412±98 mL/min in elderly subjects compared to 522±139 mL/min in younger subject (reduction by 21%) 33 .
PK of metformin after multiple doses and chronic administration
T2DM patients aged between 70-88 years received metformin at a dosage of either 850 mg or 1,700 mg/day dependent on CL CR values of 30-60 mL/min and greater than 60 mL/min, respectively. After 2 months, metformin concentrations remained in the therapeutic range and lactate levels within the reference limits in all participants, with no statistically differences between those with and without RI 34 .
Trough serum levels of metformin were measured in 137 T2DM patients with varying renal function and followed repeatedly during 2 months in 20 patients with eGFR <60 mL/min/1.73 m². Patients with eGFR >60, 30-60, and <30 mL/min/1.73 m² had median trough metformin concentrations of 4.5, 7.71 and 8.88 µmol/L, respectively. Notably, there were wide variations in these levels within each group, with few patients having serum levels > 20 µmol/L (> ~2.6 µg/mL). The median intra-individual overall coefficient of variation was around 30% 35 . In patients with severe RI (CL CR 15-40 mL/min), who were prescribed a range of metformin doses (250-2000 mg daily), few had high lactate concentrations (>2.7 mmol/L) and few had high metformin concentrations (3-5 mg/L), without correlation between metformin and lactate concentrations 36 . Whether the measurement of metformin levels actually can aid in the prediction of lactic acidosis risk remains unclear and thereby is not recommended in clinical practice 37 .
Metformin and hemodialysis
Metformin is not bound to plasma proteins, and thus should be easily dialyzable 27 . A study determined the characteristics of metformin elimination by dialysis. Metformin may be removed even after reaching an equilibrium between blood and dialysate levels in a recirculating system, suggesting a storage of metformin in a deep compartment with a gradient of concentration between this compartment and the blood. Metformin is highly dialyzable with a clearance of up to 170 mL/min under good hemodynamic conditions. Thus, hemodialysis can efficiently remove metformin, especially from patients in whom overdose is suspected, and corrects metabolic acidosis in patients with metformin-induced lactic acidosis 38 . Accurate recognition of metformin-associated lactic acidosis and prompt initiation of hemodialysis are paramount steps towards rapid recovery 39 .
Controversy about the risk of metformin in patients with CKD
Classically, CKD (CL CR < 60 mL/min) represents a contraindication to the use of metformin in patients with T2DM 40 . In case of RI, metformin may, indeed, accumulate, block gluconeogenesis and cause lactic acidosis, a harmful complication that may be fatal 41, 42 . However, recent data suggested that metformin may be administered with caution in patients with CL CR 45-60 mL/min or even lower (30-45 mL/min), provided that the daily dose is reduced by half and kidney function is regularly monitored 37 . In patients without comorbid conditions that would predispose them to lactic acidosis, elevated serum creatinine levels (or reduced GFR) should be considered a risk factor for the development of lactic acidosis but not an absolute contraindication 43 . In daily clinical practice, development of contraindications, including RI, rarely results in discontinuation of metformin therapy; nevertheless, lactic acidosis remains a rare event 44, 45 . In some studies, the prevalence of T2DM receiving metformin despite having a contraindication (including a GFR < 60 mL/min) was over 80%.
Nevertheless, metformin use in such conditions did not appear to increase the risks of lactic acidosis, hospitalization and death 46 . At least three scenarios can be proposed to explain the use of metformin in patients with RI: 1) creatinine levels are not appropriately or consistently assessed, 2) levels are normal at the time of the initial prescription of metformin and subsequent elevations go unrecognized, or 3) physicians judge that benefits of therapy outweigh potential risks 47 . In patients having T2DM with established atherothrombosis participating in the Reduction of Atherothrombosis for Continued Health (REACH) Registry, the 2-year mortality rate associated with metformin vs. other glucose-lowering agents was significantly lower in patients with an eGFR of 30 to 60 mL/min/1.73 m² (adjusted hazard ratio 0.64; 95% CI, 0.48-0.86; P=0.003) 48 . There are more and more data suggesting that meformin can be used in stable mild to moderate CKD and that not prescribing metformin in these patients may cause more harm compared to the benefits of avoiding potentially rare complications 25, 49, 50 . These observations led to a recent position statement from the ADA-EASD in which metformin may be used down to a GFR of 30 mL/min, with dose reduction advised at 45 mL/min (Table 4 ). This would lead to safely prescribing OADs in patients with an eGFR < 60 mL/min/1.73 m², and more importantly in medical practice, according to the law 51 . However, the risk of lactic acidosis should not be neglected 42, 50, 52 and the drug should be immediately stopped in presence of unstable RI, any acute event (high fever for instance), gastrointestinal disorders (diarrhea, vomiting), dehydration, ... 42, 52 .
Sulfonylureas
Sulfonylureas remain largely used in the management of T2DM and are positioned as second-line treatment after failure of metformin monotherapy 16 . They are associated with a higher risk of severe hypoglycemia, compared with metformin and more recent glucoselowering therapies 53 , especially in the elderly population and in patients with CKD 20, 54 . In a German study investigating the incidence of severe hypoglycemia and clinical characteristics to demonstrate typical risk constellations, T2DM patients were characterized by old age, low CL CR (46±24 mL/min) with RI in 73% and extensive co-medication 55 . The excessive mortality associated with hypoglycemia makes this complication a significant threat to patient safety in CKD 56 . Surprisingly, a recent retrospective analysis of the national Veterans Administration database showed that, compared to patients using metformin, sulfonylurea users had an increased risk for renal outcomes (persistent decline in eGFR from baseline of 25% or more or diagnosis of ESRD and/or death), with an adjusted hazard ratio of 1.20 57 . The reasons for these intriguing observations, which should be confirmed in further analyses, remain unknown.
Most sulfonylureas are excreted by the kidney, either the parent compound or metabolites (some of them being pharmacologically active) 41, 58 . Clinical PK of sulfonylureas has been extensively reviewed 59 . However, rather few PK studies have been performed with sulfonylureas in patients with RI and most of them are rather old and of poor quality in terms of number of subjects and PK parameters description ( 61 , were shown to be excreted by the kidney, leading to a higher risk of severe hypoglycemia in patients with CKD. Currently, they have been replaced by second-generation sulfonylureas.
Glibenclamide (glyburide)
Contrasted observations regarding glibenclamide (glyburide) have been reported with no increase in concentrations of the parent drug in patients with various degrees of CKD, but a higher incidence of severe hypoglycemia reported in T2DM patients with RI. This may be explained by the presence of two active metabolites (M1 and M2), which are also cleared by the kidneys 62 .
Glibenclamide PK in patients with RI
The PK of Finally, PK of glyburide was compared in subjects with T2DM and ESRD requiring hemodialysis and in T2DM patients with normal renal function. The mean serum glyburide blood levels and PK parameters did not differ after initial or chronic glyburide (3 mg once daily) administration in patients with ESRD treated with hemodialysis compared with controls. Glyburide t 1/2 averaged 3.3 h in control subjects and 5.0 h in hemodialysis subjects 65 .
Hypoglycemia in glibenclamide-treated patients with

RI
In a cohort of 33,243 sulfonylurea users, the rate of diagnosis of hypoglycemia made by physicians was higher for glibenclamide than for other sulfonylureas (glipizide, gliclazide, tolbutamide). Furthermore, RI was shown to be associated with an increased risk of hypoglycemia (odds ratio, OR : 4.32 ; 95% CI 2.40-7.77)
66
. A Canadian case-control study described the potentially devastating effect of sulfonylurea-based (mostly glibenclamide/glyburide) oral hypoglycemic therapy in patients with ESRD with the occurrence of severe and prolonged hypoglycemia. Patients at greatest risk appear to be those with reduced intake, previous hypoglycemic episodes, and longer duration of diabetes so that alternative drugs should be considered in these patient groups 67 . However, opposite conclusion was reported in another nested case-control study using administrative records and laboratory data from Ontario, Canada, which included outpatients 66 years of age and older with T2DM. Compared to metformin, glyburide was associated with a greater risk of hypoglycemia in patients with both normal [adjusted odds ratio -OR -: 9.0; 95% CI 4.9-16.4) and impaired renal function (OR: 6.0; 95% CI 3.8-9.5). The conclusion of this population-based study was that RI does not augment the risk of hypoglycemia associated with glyburide use in T2DM patients 68 . Nevertheless, a one-time intervention in a risk reduction project decreased glyburide use over a 3-month period in elderly outpatients with RI without compromising glucose control and with a trend for a reduction in the incidence of hypoglycemia 69 .
Glimepiride
The PK of glimepiride was investigated in a single (3 mg 58, 70 .
Glimepiride was associated with fewer episodes of severe hypoglycemia than glibenclamide in routine clinical use 53 . However, severe hypoglycemia did occur with glimepiride, especially in elderly T2DM patients with RI 71 . Uncritical prescription of sulfonylureas (including a high proportion of glimepiride in a German study) neglecting crucial contraindications -particularly RI -contributed substantially to the risk of sulfonylurea-induced hypoglycemia in these mainly geriatric patients 55 .
Glipizide
In healthy volunteers, the t 1/2 of glipizide elimination averaged 3.3 h both after intravenous and oral administration. The total plasma clearance of glipizide was 42.2±5.4 mL/min. Glipizide CL R was dependent on urinary pH, but on the average it contributed to the total clearance of the parent drug only by 5% 72 . In subjects receiving 5 mg 14 C-glipizide, 85% of the total radioactivity in plasma corresponded to unchanged glipizide. In urine, 98% of the radioactivity corresponded to more polar and more readily excreted metabolites. The administration of 14 C-glipizide to patients with RI showed that the rate of disappearance of the unchanged glipizide was approximately the same as in normal subjects, but that apparent t 1/2 of the hydroxylated metabolites was increased to 20 h and more. Because these metabolites are metabolically inactive, such accumulation of metabolites could not lead to a higher risk of hypoglycemia in T2DM patients with RI 73 . Glipizide (2.5 mg once daily, adjusted based on glycemic control to a 10-mg twice a day maximum dose) was evaluated in patients with T2DM and moderate-to-severe CKD and inadequate glycemic control. A higher incidence of symptomatic hypoglycemic episodes was observed with glipizide versus sitagliptin (17.0% versus 6.2%, respectively; P=0.001), for a comparable glucose-lowering efficacy, an observation similar to that previously reported in patients without RI 74 . Similar results were obtained in a recent study that compared the efficacy and safety of sitagliptin and glipizide monotherapy in patients with T2DM and ESRD on dialysis therapy 75 . Thus, glipizide does not increase hypoglycemia in patients with CKD
and its use appears more suitable than glibenclamide (glyburide) or even glimepiride in this population.
Gliclazide
Gliclazide is metabolized by the liver to inactive metabolites, which are eliminated mainly in the urine (80%). The PK of gliclazide was studied in 6 diabetic (mean CL CR =44 mL/min) and 11 non-diabetic (mean CL CR =13 mL/min) patients with various degrees of RI, and compared to that of 9 healthy volunteers (mean CL CR =118 mL/min). Gliclazide was absorbed similarly in all three groups. Once maximum plasma levels of gliclazide had been reached, they tended to decline more slowly in the RI groups (mean elimination half-life in diabetic group: 14.8 hours and non-diabetic group: 22.4 hours) as compared to the healthy volunteer group (12.7 hours). However, the inter-subject variability was large and the differences were not statistically significant. There were no significant differences for the other parameters measured and no significant correlation was found between any of the measured PK parameters and CL CR (data only reported as abstract form) 76 .
Although no extensive data are available in patients with severe RI, studies have shown neither PK modifications of the drug nor a higher risk of hypoglycemia in patients with a GFR > 40 ml/min 41 . In Switzerland, gliclazide is the only sulfonylurea that can be used in subjects with a GFR of 40-60 ml/min, but it has to be stopped once GFR falls below 40 ml/min 78 .
Since many years, gliclazide is available as a modified release formulation 73 . The long-term efficacy and safety of gliclazide modified release in T2DM patients with mild to moderate RI were confirmed by the results of phase III studies. Among the 507 patients who completed 2 study years, 20% of them had mild to moderate RI defined on CL CR between 20 and 80 mL/min. In these patients, the mean change in HbA1c from baseline to 2 years was similar to that of the patients with normal renal function, with no excess of hypoglycemic episodes 79 .
In the European GUIDE study, which randomized 845 T2DM patients (almost 42% with a CL CR < 80 mL/min) to either gliclazide modified release 30-120 mg daily or glimepiride 1-6 mg daily, gliclazide was as effective as glimepiride, but with a significantly lower risk of hypoglycemia 80 . One proposed explanation was that the two drugs show different PK profiles with the occurrence of an active metabolite eliminated by the kidney for glimepiride and no circulating active metabolite for gliclazide, consistent with the higher incidence of hypoglycemia in patients with RI 80 .
In the large prospective ADVANCE ("Action in Diabetes and Vascular Disease:
Preterax and Diamicron Modified Release Controlled Evaluation") trial, a strategy of intensive glucose control, involving gliclazide (modified release) and other drugs as required, that lowered the glycated hemoglobin (HbA 1c ) value to 6.5% yielded a 21% significant reduction in the incidence of nephropathy (4.1% vs. 5.2%; hazard ratio, 0.79; 95% CI 0.66-0.93; P=0.006). The component of new or worsening nephropathy most clearly reduced through intensive glucose control was the development of macroalbuminuria, with only a trend toward a reduction in the need for renal-replacement therapy or death from renal causes but no effect on the doubling of serum creatinine level. In this population, which comprised a majority of patients with normal kidney function, gliclazide was well tolerated, with uncommon hypoglycemia 81 .
Gliquidone
Gliquidone is rapidly and almost completely absorbed after oral administration, and has a short elimination half-life (around 1.5 h). It is metabolized in the liver so that accumulation does not take place in patients with RI 41, 82 . However, there are no large scale studies published with this sulfonylurea, which is only commercialized in few countries.
Meglitinides (glinides)
Compared to sulfonylureas, glinides are characterized by shorter half-lifes as well as by the absence of significant renal excretion 83, 84 . Thus, in principle, they may be used in patients with CKD, without dose adjustment 85 . This conclusion may be drawn from PK studies in patients with RI, with repaglinide 86 and nateglinide (although some caution is required for nateglinide because of the presence of an active metabolite that is cleared by the kidney). 87 However, there are no large scale studies having assessed both the efficacy and the safety of glinides in T2DM patients with CKD 83 . Furthermore, these compounds are exposed, as sulfonylureas, to drug-drug interactions 88 .
Repaglinide
PK comparison with single and multiple doses of repaglinide (2 mg repaglinide for 7 days) was performed in subjects with normal renal function and subjects with various degrees of RI (mild to moderate; severe; hemodialysis). PK parameters did not show significant changes after single or multiple doses of repaglinide, although the elimination rate constant in the group with severe RI decreased after 1 week of treatment. Subjects with severe RI had significantly higher exposure (AUC values) after single and multiple doses of repaglinide than subjects with normal renal function ( Table 1) . No significant differences in values for serum C max or T max were detected between subjects with RI and those with normal renal function.
Hemodialysis did not significantly affect repaglinide clearance. Repaglinide was safe and well tolerated in subjects with varying degrees of RI. Although adjustment of starting doses of repaglinide is not necessary for RI or renal failure, severe impairment may require more care when upward adjustments of dosage are made 89 .
In clinical trials of up to 52 weeks' duration and in the clinical practice setting, recommended dosages of repaglinide (0.5-4 mg three times daily) provided effective glycemic control and were generally well tolerated in patients with T2DM, including those with RI 83 . Thus, repaglinide is an appropriate treatment choice, even for individuals with more severe degrees of RI 86 .
Nateglinide
Diabetic patients with RI or ESRD undergoing hemodialysis received a single 120 mg dose of nateglinide immediately before breakfast. Plasma nateglinide concentrations increased rapidly and similarly in patients undergoing dialysis and matched healthy subjects and was comparable in patients with RI and controls. There were no statistically significant differences for C max or AUC between the groups (Table 1) . Nateglinide was eliminated rapidly in all groups (t 1/2 = 1.9-2.8 h). There was no correlation between the level of renal function and systemic exposure. There was a low extent of renal excretion of nateglinide in healthy subjects (11%) and diabetic patients with RI (3%). Nateglinide was well tolerated. These data suggested that nateglinide is suitable for use in diabetic patients with CKD or with ESRD undergoing dialysis. No dose adjustment appears necessary in renally impaired patients 87 .
In another study, single 90 mg dose of nateglinide was safe and effective in patients with renal failure 90 . However, repeated administrations could cause prolonged hypoglycemia due to accumulation of M1, a metabolite that is known to have a modest hypoglycemic activity 91 . Hemodialysis may help to eliminate excessive accumulation of M1 90 .
Mitiglinide
Although mitiglinide was effective as a treatment for diabetic patients on hemodialysis therapy, it should be initiated at a lower dose in this population, compared with the general population of diabetic patients, in order to avoid hypoglycemia 
Acarbose
Acarbose acts locally within the gastrointestinal tract and is characterized by a low systemic bioavailability 93 . Although <2% of an oral dose of acarbose was absorbed as active drug, patients with severe RI (CL CR <25 mL/min) attained increases about 5-fold higher for peak plasma concentration of acarbose and 6-fold higher for AUC values than subjects with normal renal function 13 . Because long-term clinical trials in diabetic patients with significant renal dysfunction have not been conducted, treatment of T2DM patients with acarbose is not recommended 2 .
Miglitol
Miglitol is systemically absorbed but is not metabolized, and is rapidly eliminated by renal excretion as unchanged drug 94 . Patients with CL CR <25 mL/min taking miglitol 25 mg 3 times daily exhibited a greater than 2-fold increase in miglitol plasma levels when compared to subjects with CL CR >60 mL/min 13 . Dose adjustment to correct for the increased plasma concentrations is not feasible because miglitol acts locally in the gut. Treatment of patients with CL CR <25 mL/min with miglitol is not recommended because the safety of miglitol in these patients has not yet been elucidated 13 .
Voglibose
Voglibose is an alpha-glucosidase inhibitor only commercialized in Japan. It has no renal excretion 13 . Two studies showed that it can be safely used in diabetic patients on hemodialysis, in combination with pioglitazone or mitiglinide 95, 96 .
Thiazolidinediones
The experimental studies that evaluated the potential beneficial effects of peroxisome proliferator-activated receptor-gamma (PPARγ) agonists (TZDs : pioglitazone, rosiglitazone) on renal function have been reviewed. In that paper, the efficacy, tolerability and safety results of TZD use in patients with different degrees of RI, in dialysis patients, and in diabetic patients after kidney transplantation were revised 97 . Data from several animal and human studies support the notion that TZDs reduce urine albumin excretion and may prevent development of renal injury 98 . From a PK point of view, TZDs are metabolized in the liver and not excreted by the kidney. Therefore, no dose adjustments are required in patients with CKD. However, the safety of TZDs has been questioned and some safety concerns may be even more relevant in a diabetic population with CKD 
Pioglitazone
Because pioglitazone and its active metabolites are excreted mainly via the liver, these PK properties are ideally suited for patients with CKD 105 . Healthy subjects with normal renal function (CL CR > 80 mL/min), patients with moderate RI (CL CR 30-60 mL/min) and patients with severe RI (CL CR < 30 mL/min) received single and multiple oral doses of pioglitazone 45 mg. The serum PK profiles of pioglitazone and its metabolites M-III and M-IV were assessed for the first and last dose administered (day 1 and day 12, respectively). PK data were similar in subjects with normal and with moderate RI and revealed no significant accumulation of pioglitazone or its metabolites in patients with RI. Mean AUC values were decreased (rather than increased) in patients with severe RI compared with healthy subjects with normal renal function for pioglitazone and its M-III and M-IV metabolites (Table 1 ) This may be explained by reduced protein binding, which is common in patients with RI, resulting in increased free pioglitazone concentrations and increased total clearance of the drug (assuming that the intrinsic capacity of the liver remains unchanged). In this study, pioglitazone was well tolerated in patients with varying degrees of RI so that adjustment of starting and maintenance doses in these patients is probably unwarranted 106 . PK profile of pioglitazone was also shown to be similar in patients with ESRD undergoing hemodialysis and in patients with normal renal function 107 . In T2DM patients on hemodialysis, pioglitazone treatment resulted in better glycemic control, improved lipid levels, an increase in insulin sensitivity and adiponectin levels, a decrease in inflammatory markers and a reduction in erythropoietin dose, thus improving the risk factors of cardiovascular disease 
Rosiglitazone
Rosiglitazone is mainly metabolized by CYP2C8 into inactive metabolites, and < 1% of the parent drug appears in the urine in unchanged form 111 . To investigate the effect of varying degrees of CKD on the PK of rosiglitazone after a single dose of 8 mg, subjects were stratified by estimated CL CR : normal (> 80 mL/min), mild RI (60-80 mL/min), moderate RI (30-59 mL/min), and ESRD not requiring dialysis (< 30 mL/min) 112 . Slight increases (approximately 10%-20%) in mean unbound AUC ∞ values were observed for each RI group compared to the normal group but were not considered to be clinically relevant.
Patients with severe RI exhibited a 38% increase in mean fraction unbound, leading to an increase in total clearance, which resulted in a 19% to 24% lower mean total AUC ∞ and C max values relative to the normal group. The rates of adverse events were similar for all groups.
As RI does not markedly alter the PK of total or unbound rosiglitazone following a single dose of rosiglitazone, the starting dose does not need to be adjusted in patients with CKD. Subsequent dose adjustments should be based on individual patient response 112 .
The PK and tolerability of a single 8 mg oral dose of rosiglitazone were compared in ESRD patients undergoing hemodialysis and 10 healthy volunteers. Hemodialysis did not influence rosiglitazone PK, and dialytic clearance was low (0.10 L/h). Mean AUC ∞ , C max and t 1/2 for rosiglitazone were similar in hemodialysis patients and healthy individuals. Thus, rosiglitazone dose adjustments are not warranted in patients with T2DM with ESRD on hemodialysis 113 . The PK of a single 8 mg oral dose of rosiglitazone was studied in patients with ESRD and requiring long-term chronic ambulatory peritoneal dialysis. Mean AUC ∞ and C max of rosiglitazone in patients with peritoneal dialysis appear no different from those reported in healthy volunteers 114 .
In a post-hoc analysis of data pooled from 3 randomized, double-blind, placebocontrolled studies, the effects of rosiglitazone 4 mg when added to a sulfonylurea regimen were investigated in patients with T2DM and mild to moderate RI (baseline CL CR of 30 to 80 mL/min). Rosiglitazone was effective and well tolerated in this population, with no obvious differences with results observed in patients with normal kidney function 115 . In two other studies, rosiglitazone was well tolerated and beneficial in patients with T2DM on peritoneal dialysis therapy 116 or undergoing regular hemodialysis 117 .
DPP-4 inhibitors
DPP-4 inhibitors (gliptins) are a new class of OADs belonging to the incretin-based
glucose-lowering agents. They improve glucose control without inducing hypoglycemia (in contrast to sulfonylureas) and are weight-neutral 118 . Several molecules are already available, which are characterized by different PK properties 119, 120 . DPP-4 inhibitors have been particularly well studied in patients with CKD Several studies have demonstrated that the glucose-lowering efficacy is maintained while a good safety profile when reduced doses of these gliptins are used in patients with RI [127] [128] [129] [130] . In contrast, linagliptin is mainly excreted by the biliary route rather than by the kidney (< 5 %) 131 . Therefore, this DPP-4 inhibitor does not require any dose adjustment in case of RI and can be used in patients with various degrees of CKD (Table 5) 132, 133 . In all studies involving DPP-4 inhibitors, the following populations were tested : normal kidney function, CL CR > 80 ml/min; mild RI, 50-80 mL/min; moderate RI, 30-50 mL/min; severe RI, <30 mL/min; ESRD, <30 mL/min undergoing hemodialysis. DPP-4 inhibitors are playing an increasing role in the management of T2DM, especially in combination with metformin. Several fixed-dose combinations (FDCs) are currently available or will be commercialized very soon 118 . Such FDCs may only be prescribed when both compounds are not contraindicated because of the presence of RI and appropriate adjustments of individual doses may be required [134] [135] [136] .
Sitagliptin
The PK of single doses of sitagliptin 50 mg was evaluated in patients with various degrees of RI : mild, moderate, severe, ESRD on hemodialysis, and normal renal function 122 .
Increases in sitagliptin AUC ∞ were ∼1.6-fold, ∼2.3-fold, ∼3.8-fold, and ∼4.5-fold higher for patients with mild, moderate, severe RI and ESRD, respectively, as compared to levels obtained in subjects with normal renal function ( Table 1) . Based on these findings, sitagliptin dose adjustments are recommended for patients with moderate RI (50 mg daily) or severe RI or ESRD (25 mg daily) to provide plasma sitagliptin exposure comparable to patients with normal renal function (100 mg daily) ( Table 5 ).
Sitagliptin was generally well tolerated and provided effective glycemic control in patients with T2DM and moderate to severe RI, including patients with ESRD on dialysis 128 .
In patients with T2DM and moderate to severe CKD, sitagliptin (50 to 25 mg/day respectively) and glipizide provided similar HbA 1c -lowering efficacy. Sitagliptin was generally well-tolerated, with a lower risk of hypoglycemia and weight loss versus weight gain, relative to glipizide 74 . In patients with T2DM and ESRD on dialysis therapy, sitagliptin 25 mg/day was almost as effective in reducing HbA1c as glipizide (non significant difference of 0.15% after 54 weeks), with a lower incidence of symptomatic hypoglycemia (6.3 % vs.
10.8%) and severe (0% vs. 7.7%) hypoglycemia 75 .
Vildagliptin
Vildagliptin is primarily metabolized via hydrolysis and the metabolites are predominantly excreted by the kidneys. To a smaller extent, vildagliptin is also excreted by the kidneys as the unchanged drug (23% after an oral dose). Therefore, RI may have certain effects on the PK of vildagliptin 123 . The mean AUC values increased by 32-134% and the C max values increased by 8-66% in subjects with mild, moderate and severe RI, and ESRD on hemodialysis, compared with healthy subjects. CL R of vildagliptin in healthy volunteers averaged 12.4 L/h, and decreased in subjects with varying degrees of RI with a significant correlation with the reduction in GFR (r²=0.75). However, the total exposure (AUC) to vildagliptin did not show a clear correlation with the severity of RI (assessed by GFR).
Vildagliptin was removed by hemodialysis to a limited extent (3%). Compared with values in
healthy subjects, exposure (AUC) to the major and inactive hydrolysis metabolite (LAY151) in subjects with mild, moderate and severe RI, and in those with ESRD was increased by 1.6-, 2.4-, 5.4-and 6.7-fold, respectively, with a good correlation between changes in exposure to LAY151 and GFR reduction 124 ( Table 1) . The lack of a clear correlation between the increased exposure to vildagliptin and the severity of RI may indicate that the kidneys contribute not only to the excretion but also, and predominantly, to the hydrolysis metabolism of vildagliptin. From a PK perspective, the approximate 2-fold increase in exposure suggests that the dose of vildagliptin for patients with moderate and severe RI should be reduced to half of the daily dose for patients with normal renal function (50 mg once daily instead of 50 mg twice daily) ( Table 5) 123 .
In a 24-week study of 515 patients with T2DM and moderate or severe RI, vildagliptin (50 mg once daily) added to ongoing antidiabetic therapy had a safety profile similar to placebo and elicited a statistically and clinically significant decrease in HbA 1c 129 . These results were confirmed after a 1-year observation 130 . In another study, the safety profile of vildagliptin 50 mg as an add-on to metformin was similar in patients with mild RI and normal renal function 137 . In a pooled analysis of 38 studies where vildagliptin was given for weeks in patients with T2DM, the presence of mild RI did not adversely affect the safety of vildagliptin relative to patients with normal renal function 138 . Finally, vildagliptin was also effective and safe as a treatment for diabetic patients undergoing hemodialysis 139 or in patients with severe RI (eGFR < 30 mL/min/1.73 m² and longstanding T2DM not adequately controlled with insulin therapy 140 .
Saxagliptin
The PK of saxagliptin and its pharmacologically active metabolite, 5-hydroxy saxagliptin, in nondiabetic subjects with mild (CL CR 50-80 ml/min), moderate (30-50 ml/min), severe RI (<30 ml/min), or ESRD were compared with saxagliptin and metabolite PK and tolerability in healthy adult subjects. 125 All subjects received a single oral dose of saxagliptin 10 mg. Using a model-based approach and compared with healthy subjects, the geometric mean AUC ∞ for saxagliptin was 16%, 41% and 108% higher in subjects with mild, moderate or severe RI, respectively. AUC ∞ values for 5-hydroxy saxagliptin were 67%, 192% and 347% higher in subjects with mild, moderate or severe RI, respectively (Table 1) .
Elimination t 1/2 of saxagliptin and 5-hydroxy saxagliptin progressively increased while corresponding CL R progressively decreased according to the reduction of CL CR .
Consequently, one-half the usual dose of saxagliptin 5 mg (i.e. 2.5 mg orally once daily) is recommended for patients with moderate or severe RI or ESRD on hemodialysis, but no dose adjustment is recommended for those with mild RI.
A 12-week study evaluated the efficacy and safety of saxagliptin 2.5 mg versus placebo in patients with T2DM and RI (CL CR < 50 mL/min) 141 . Oral antihyperglycemic drugs and insulin therapy present at enrolment were continued throughout the study. Adjusted mean HbA 1c decreases from baseline to week 12 were numerically greater with saxagliptin than with placebo in the subgroups of patients with moderate (≥ 30 CL CR < 50 mL/min) and severe (CL CR < 30 mL/min) RI, but not in ESRD patients on hemodialysis. After an extended follow up of 52 weeks, adjusted mean decrease in HbA 1c was greater with saxagliptin than placebo (difference, -0.73%, p<0.001). Reductions in HbA 1c were numerically greater with saxagliptin 2.5 mg than placebo in patients with RI rated as moderate or severe, but similar to placebo for those with ESRD on hemodialysis. Saxagliptin was generally well tolerated, with similar proportions of patients reporting hypoglycemic events as in the placebo group. Thus, saxagliptin 2.5 mg once daily offers sustained efficacy and good tolerability for patients with T2DM and moderate to severe RI, but should not be recommended in patients with ESRD (Table 5) 127 .
Alogliptin
The results of a single-dose (50 mg) PK study in patients with RI showed an increase in alogliptin exposure compared with healthy volunteers: approximately 1.7-, 2.1-, 3.2-, and 3.8-fold increase in patients with mild, moderate, and severe RI, and in patients with ESRD, respectively ( Table 1) 126 . Based on these findings, to achieve plasma alogliptin concentrations comparable to those in patients with normal renal function, alogliptin dose adjustments are recommended for patients with T2DM and moderate to severe RI, including those with ESRD requiring dialysis (Table 5 ).
Linagliptin
The influence of various degrees of RI on the exposure of linagliptin was assessed in subjects with and without T2DM 142 . Linagliptin PK (5 mg once daily) was studied under single-dose and steady-state conditions (administration for 7-10 days) in subjects with mild, moderate, and severe CKD and ESRD on hemodialysis, and compared with the PK in subjects with normal renal function. Renal excretion of unchanged linagliptin was <7% in all groups.
Although there was a tendency towards slightly higher (20-60%) exposure in subjects with CKD compared with subjects with normal renal function, the steady-state AUC and C max values showed a large overlap and were not affected by the degree of RI (Table 1) 
SGLT2 inhibitors
The kidney plays a major role in glucose homeostasis because of its role in gluconeogenesis and the glomerular filtration and reabsorption of glucose in the proximal convoluted tubules. The transport of glucose from the tubule into the tubular epithelial cells is accomplished by sodium-glucose co-transporters (SGLTs), especially SGLT2, a highcapacity, low-affinity transporter expressed chiefly in the kidney. SGLT2 accounts for approximately 90% of glucose reabsorption. SGLT2 inhibitors are new glucose-lowering agents, which specifically target the kidney by blocking the reabsorption of filtered glucose, thus leading to glucosuria. This mechanism of action holds potential promise for patients with T2DM not only in terms of improvements in glycemic control, but also potential benefits on weight loss and arterial blood pressure reduction 144 . Dapagliflozin is the SGLT2 inhibitor with the most clinical data available to date 145 . Other SGLT2 inhibitors (canagliflozin, empagliflozin) are currently in late phase of development, but no specific PK studies in patients with RI have been published so far with these last two compounds 144 . In a study investigating potential drug-drug interactions between empagliflozin and metformin in healthy men, the renal clearance of empagliflozin and metformin were unaffected by coadministration 146 .
A study assessed the effect of differences in renal function on the PK/PD of dapagliflozin. A single 50 mg dose of dapagliflozin was administered in five groups of individuals: healthy nondiabetic subjects; patients with T2DM and normal kidney function; and patients with T2DM and mild, moderate or severe RI based on eGFR. Subsequently, multiple doses (20 mg once daily) were evaluated in the patients with T2DM. Plasma concentrations of dapagliflozin and D3OG, an inactive metabolite, were incrementally increased with declining kidney function. Steady-state C max for dapagliflozin were 4%, 6%
and 9% higher and for D3OG were 20%, 37% and 52% higher in patients with mild, moderate, and severe RI, respectively, compared to normal function. AUC 0-tau was likewise higher (Table 1) . Compared to patients with normal renal function, glucose-lowering effects were attenuated with RI. Steady-state renal glucose clearance was reduced by 42%, 83%, and 84% in patients with mild, moderate, or severe RI, respectively. These results indicate that the kidney, besides the liver, significantly contributes to dapagliflozin metabolism, resulting in higher systemic exposure with declining kidney function. Dapagliflozin reduced pharmacodynamics in diabetic subjects with moderate to severe RI are consistent with the observation of reduced efficacy in terms of HbA 1c diminution in this patient population 147 .
GLP-1 receptor agonists
When oral therapy is not sufficient to control blood glucose, injectable agents may be used. Besides insulin therapy, GLP-1 receptor agonists (exenatide and liraglutide, soon lixisenatide) offer new opportunities for the management of T2DM 16 . However, because of PK properties of these compounds, some limitations have been pointed out in presence of RI (Table 5) .
Published case reports have documented the relationship between exenatide 148, 149 or liraglutide 150 use and acute kidney injury in patients with T2DM. The proposed explanation was the occurrence of gastrointestinal side effects with recurrent vomiting leading to dehydration and secondary acute RI. Physicians should be aware of this adverse event and patients should also be educated about the need to report unusual or prolonged gastrointestinal symptoms. However, a retrospective cohort study of a large medical and pharmacy claims database revealed an increased incidence of acute renal failure in diabetic versus non-diabetic patients but no association between use of exenatide and acute renal failure 151 .
Exenatide
PK, safety and tolerability of a single exenatide dose were evaluated in patients with RI. Exenatide (5 or 10 µg) was injected subcutaneously in 31 subjects (only one with T2DM) stratified by renal function : normal (CL CR >80 mL/min, mild RI (51-80 mL/min), moderate RI (31-50 mL/min) or end-stage renal disease (ESRD) requiring hemodialysis 152 . PK data were combined with four previous single-dose studies in patients with T2DM to explore the relationship of exenatide clearance (CL/F) and CL CR . Mean t 1/2 for healthy, mild RI, moderate RI and ESRD groups were 1.5, 2.1, 3.2 and 6.0 h, respectively. After combining data from multiple studies, least squares geometric means for CL/F in subjects with normal renal function, mild RI, moderate RI and ESRD were 8.14, 5.19, 7.11 and 1.3 L/h, respectively. Thereby, exposure (AUC) to exenatide was markedly increased in patients with ESRD (Table   1 ). Exenatide was generally well tolerated in the mild and moderate RI groups, but not in subjects with ESRD due to nausea and vomiting. Since tolerability and PK changes were considered clinically acceptable in patients with mild to moderate RI, it would be appropriate to administer exenatide to these patients without dosage adjustment. However, poor tolerability and significant changes in PK make the currently available therapeutic doses (5 and 10 µg) unsuitable in severe RI or ESRD 152 .
Liraglutide
To investigate whether dose adjustment of the once-daily human GLP-1 analogue liraglutide is required in patients with varying stages of RI, 30 subjects were given a single dose of liraglutide, 0.75 mg subcutaneously. No clear trend for change in PK was evident across groups with increasing renal dysfunction. The regression analysis of log(AUC) for subjects with normal renal function and mild-to-severe RI showed no significant effect of decreasing CL CR on the PK of liraglutide. Degree of RI did not appear to be associated with an increased risk of adverse events. Because renal dysfunction was not found to increase exposure of liraglutide, T2DM patients with RI should use standard treatment regimens of liraglutide. There is, however, currently limited experience with liraglutide in patients beyond mild-stage CKD 153 .
To determine the effect of mild RI on the efficacy and safety of liraglutide in patients with T2DM, the six LEAD ("Liraglutide Effect and Action in Diabetes") clinical trials were examined in a meta-analysis focusing on data from patients with normal renal function (CLCR > 89 mL/min), mild RI (60-89 mL/min), and moderate or severe RI (< 60 mL/min).
The population contained patients administered once-daily liraglutide (1.2 or 1.8 mg) or placebo as either monotherapy or in combination with oral antidiabetes drugs for 26 weeks.
Mild RI did not affect the estimated treatment differences in HbA1c, body weight and systolic blood pressure. Liraglutide treatment was safe and well tolerated in patients with mild RI, as there were no significant differences in changes in rates of renal injury, minor hypoglycemia, or nausea vs. placebo. Nevertheless, a trend towards increased nausea was observed in patients with moderate or severe RI receiving liraglutide although the number of patients in this treatment group was too low to determine statistical significance. The conclusion was that mild RI had no effect on the efficacy and safety of liraglutide 154 .
Insulin and insulin analogs
Human Insulin
The kidney plays a pivotal role in the clearance and degradation of circulating . It is generally recommended that when the GFR decreases to between 10 and 50 mL⁄ min, the insulin dosage should be reduced by 25%, and when the GFR decreases to <10 mL⁄min, the insulin dosage should be reduced by 50% from previous amounts 8, 9 . The reduction in insulin requirement in RI is similar in type 1 and insulin-treated T2DM patients.
In subjects with T2DM, the residual insulin secretion has no impact on the reduction in insulin requirement dependent on the GFR. As an example, the insulin dose required by T2DM patients was reduced by 51% in patients with a CL CR of 10 mL/min compared to patients with a CL CR of 80 mL/min 158 .
11.2.
Insulin analogs
Modifications of the insulin molecule have resulted in two long-acting insulin analogs (glargine and detemir) and three rapid-acting insulins (aspart, lispro, and glulisine) with improved PK/PD profiles. As for human insulin, the PK/PD profiles for insulin analogs may be influenced by many variables including renal function, although the available data are rather scarce 159 . Insulin lispro maintains its characteristic PK/PD properties in patients with overt diabetic nephropathy 160 . In hemodialysis patients with diabetes, lispro insulin is absorbed faster than regular insulin, as it is in individuals with normal kidney function 161 .
Similarly, RI does not affect the PK of insulin aspart in a clinically significant manner 162 . To our knowledge, there are no published studies that have specifically tested the PK of the two long-acting insulin analogs, glargine or detemir, in patients with CKD 159 . Reduction of initial glargine/glulisine insulin weight-based dosing in hospitalized patients with T2DM and RI reduced the frequency of hypoglycemia by 50% without compromising the control of hyperglycemia 163 . Short-acting insulin analog can also be used in hemodialysis patients with 
Conclusion
A quite large and increasing proportion (currently around 20-25%) of T2DM patients have moderate to severe CKD (stages 3-5), especially in the elderly population, which requires the adaptation of the glucose-lowering therapy. Indeed, RI exerts a major influence on PK of most oral and injectable antidiabetic agents. Therefore, the daily dosage should be reduced in most instances or, if CKD is severe enough, the medication should not be initiated or be stopped for safety reasons (Figure 1 ). Clinical experience in various countries, however, demonstrates that numerous T2DM patients are not appropriately treated, as they are receiving too high dosages of the medications according to the reduced renal function or even they are treated by drugs that are contraindicated considering the severity of CKD. Despite these inappropriate prescriptions, the incidence of severe adverse events is rather low, even if it may be somewhat underestimated in clinical practice. The most well recognized side effects when glucose-lowering drugs are prescribed in T2DM patients with RI are lactic acidosis with metformin, hypoglycemia with sulfonylureas (more rarely with glinides) but also with insulin (or insulin analogs), and fluid retention with a higher risk of congestive heart failure with TZDs. The PK of DPP-4 inhibitors (except linagliptin) and GLP-1 receptor agonists is also modified by RI, which may require appropriate dose reductions. However, the potential risk associated with these compounds, even if used in patients with CKD, is less well established.
Whatsoever, the risk of hypoglycemia that may be dangerous, and even fatal, with sulfonylureas in patients with CKD could be markedly reduced by using DPP-4 inhibitors instead of sulfonylureas in this population. The case of metformin deserves more attention.
Indeed, metformin is the first-line OAD in all guidelines for the management of T2DM, but it is also officially contraindicated in patients with GFR below 60 mL/min. If this rule is strictly respected (which is frequently not the case in real life !), this will deprive numerous patients of the best glucose-lowering agent. This situation should lead to an amendment of the rules of prescription of metformin in patients with mild to moderate RI. Finally, the experience with SGLT2 inhibitors, the only glucose-lowering drugs that specifically target the kidney, is still limited, although this new pharmacological class has already shown a reduced pharmacodynamic activity in patients with CKD and thereby is not best suited for this population.
The increasing prevalence of patients with T2DM and CKD, especially among elderly people, requires regular monitoring of renal function and appropriate selection and dosing of glucose-lowering agents according to GFR. A careful benefit/risk balance assessment should be performed in these more fragile diabetic patients. It would be of clinical interest in the future to develop new antidiabetic agents that may be used efficaciously and safely in the large population with T2DM and CKD.
EXPERT OPINION SECTION
According to the recent ADA-EASD position statement, the management of hyperglycemia of T2DM should be patient-centered. Generally speaking, the objectives and the modalities of therapy should be adapted to the characteristics of the T2DM patient. CKD is a common complication of T2DM, especially in the elderly population whose proportion is rapidly increasing, notably because of a better cardiovascular protection of patients with T2DM. The first step is to use appropriate methods to quantitatively assess and follow renal function. Current non-uniform use of different equations leads to more confusion rather than help with renal dosing and there is need for greater standardization of eGFR estimations.
Secondly, in a patient-centered approach, the presence of CKD is obviously an important condition to be taken into account, more specifically in the selection, dosing and supervision of pharmacological therapies. In T2DM patients with CKD, the treatment algorithm that may be proposed is the following one, although there are no official guidelines in this specific population.
-The first choice drug may remain metformin provided that RI is stable, the CL CR is above 30 ml/min and the renal function can be regularly monitored. When CL CR is below 45 ml/min, the daily dose of metformin should be reduced by half and the medication should be stopped when CL CR falls below 30 ml/min. Noteworthy, the patient and his/her family should be duly informed that metformin must be stopped in any acute condition, especially any situation that may lead to dehydration (diarrhea, vomiting, …) to reduce the risk of lactic acidosis (a rare but possibly fatal complication).
-In case of contraindication to metformin (CL CR between 30-45 ml/min but at risk of destabilisation or CL CR < 30 ml/min), the physician may chose a DPP-4 inhibitor rather than a sulfonylurea in order to reduce the incidence of sulfonylurea-associated hypoglycemia in patients known to be exposed to this severe complication.
Linagliptin, which is not excreted by the kidneys, may be administered at the usual dose whereas the daily dose of other DPP-4 inhibitors should be reduced (generally by half) to reach comparable plasma levels. Thereby, a similar glucose-lowering activity can be achieved, with a good safety profile, in T2DM patients with moderate to severe CKD as compared to patients with normal kidney function. Alternatively, to reduce the cost, a glinide or a sulfonylurea with low renal excretion (and without active metabolite) may also be considered. A thiazolidinedione (currently pioglitazone only, as rosiglitazone is now withdrawn in most countries because of cardiovascular safety) may also be used without dosage adjustment, although the risk of fluid retention and congestive heart failure may be increased in more fragile patients with CKD. In the Asian population, alpha-glucosidase inhibitors might also be a valuable option, although almost no data are available in CKD patients with this pharmacological class that deserves further specific studies in this population.
-When individually-targeted glucose control cannot be achieved or maintained with metformin monotherapy, the addition of a DPP-4 inhibitor appears to offer some advantages compared to sulfonylureas (again, less hypoglycemia, no weight gain, no need of titration). Several gliptin plus metformin FDCs are currently available to facilitate the use of such combination and improve adherence to therapy. The abovementioned pharmacological alternatives (repaglinide, pioglitazone, acarbose) may also be considered, although few controlled clinical trials are available in this population with CKD and thus the clinical evidence is rather scarce.
-When the gliptin-metformin combination fails, the shift to insulin therapy is probably the best option, owing to the current limited experience with triple oral therapies or injectable GLP-1 receptor agonists in patients with CKD. It is worth noting that insulin daily doses are generally lower in patients with CKD than in patients without CKD, because the kidneys clear about 50% of circulating insulin and diabetic patients with RI are more exposed to hypoglycemia. The PK of various insulin preparations (including insulin analogs) has not been well studied in patients with varying degrees of RI, and there are no absolute guidelines defining appropriate dosing adjustments of insulin that should be made based on the level of GFR.
-Finally, SGLT2 inhibitors are the only antidiabetic agents that specifically target the kidney to improve glucose control. However, their clinical efficacy vanishes as renal function diminishes so that these novel glucose-lowering medications should not be used in patients with CKD. Their safety profile is also poorly known in this population.
Because of the increasing prevalence of CKD (especially mild to moderate stages) in patients with T2DM, there is an urgent need for a clarification of the use of glucose-lowering agents in this population and for the development of new agents that are efficacious and safe to control hyperglycemia despite impaired renal function.  Renal function should be measured in all diabetic patients before prescribing any glucose-lowering agent and regularly monitored to detect worsening, especially when events that may potentially deteriorate renal function occur.
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 The pharmacokinetics of almost all glucose-lowering agents may be altered by renal impairment, thus requiring appropriate dosage adjustments according to the reduction in glomerular filtration rate (creatinine clearance).
 Metformin, the first choice oral antidiabetic agent, is officially contraindicated when creatinine clearance is < 60 ml/min/1,73 m², although real life data show that this drug is largely prescribed in patients with lower creatinine clearance without any problem and with potential benefits. In more recent guidelines, a dose reduction is proposed below < 45-60 ml/min/1,73 m², and the drug must be stopped at 30 ml/min/1,73 m².
 Most sulfonylureas are excreted by the kidneys (either parent drug or active metabolites), explaining why these drugs expose to a higher risk of (severe) hypoglycemia in diabetic patients with chronic kidney disease. DPP-4 inhibitors, whose dosage should also be Additional caution is required in patients at risk for acute kidney injury or with anticipated significant fluctuations in renal status, based on previous history, other comorbidities, or potentially interacting medications. 
